Latest Insider Transactions at Dia Medica Therapeutics Inc. (DMAC)
This section provides a real-time view of insider transactions for Dia Medica Therapeutics Inc. (DMAC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of DiaMedica Therapeutics Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of DiaMedica Therapeutics Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 28
2024
|
Jan Stahlberg > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+18.69%
|
$2,400,000
$2.5 P/Share
|
|
Jun 28
2024
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,200,000
+17.84%
|
$2,400,000
$2.5 P/Share
|
|
Jan 02
2024
|
Charles Pauling Semba Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,375
+19.25%
|
$18,750
$2.8 P/Share
|
|
Jan 02
2024
|
Richard Kuntz Director |
BUY
Grant, award, or other acquisition
|
Direct |
14,285
+50.0%
|
$28,570
$2.8 P/Share
|
|
Jan 02
2024
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,357
+9.83%
|
$60,714
$2.8 P/Share
|
|
Jan 02
2024
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
21,428
+26.34%
|
$42,856
$2.8 P/Share
|
|
Jan 02
2024
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,196
+5.0%
|
$38,392
$2.8 P/Share
|
|
Nov 16
2023
|
David J. Wambeke Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+3.66%
|
$40,000
$2.46 P/Share
|
|
Jun 23
2023
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,470,588
+25.37%
|
$4,411,764
$3.4 P/Share
|
|
Jun 23
2023
|
Randall Michael Giuffre Director |
SELL
Bona fide gift
|
Direct |
15,000
-4.16%
|
-
|
|
Jun 23
2023
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
65,000
+15.28%
|
$195,000
$3.91 P/Share
|
|
Jun 23
2023
|
Dietrich John Pauls President and CEO |
BUY
Open market or private purchase
|
Direct |
12,787
+15.71%
|
$38,361
$3.91 P/Share
|
|
Jun 23
2023
|
Charles Pauling Semba Director |
BUY
Open market or private purchase
|
Direct |
12,787
+29.93%
|
$38,361
$3.91 P/Share
|
|
Jun 23
2023
|
Scott Kellen CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+23.65%
|
$30,000
$3.91 P/Share
|
|
Jun 23
2023
|
David J. Wambeke Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
38,364
+7.03%
|
$115,092
$3.91 P/Share
|
|
Jun 23
2023
|
Richard D. Pilnik Director |
BUY
Open market or private purchase
|
Direct |
38,363
+13.39%
|
$115,089
$3.91 P/Share
|
|
Apr 10
2023
|
David J. Wambeke Chief Business Officer |
BUY
Open market or private purchase
|
Direct |
468,750
+50.0%
|
$468,750
$1.6 P/Share
|
|
Jan 03
2023
|
Amy L. Burroughs Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,156
+18.97%
|
$17,156
$1.53 P/Share
|
|
Jan 03
2023
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
35,130
+10.63%
|
$35,130
$1.53 P/Share
|
|
Jan 03
2023
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
55,555
+20.93%
|
$55,555
$1.53 P/Share
|
|
Jan 03
2023
|
Charles Pauling Semba Director |
BUY
Grant, award, or other acquisition
|
Direct |
17,156
+50.0%
|
$17,156
$1.53 P/Share
|
|
Dec 09
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
37,079
+12.47%
|
$37,079
$1.43 P/Share
|
|
Dec 08
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
20,000
+8.23%
|
$20,000
$1.4 P/Share
|
|
Dec 07
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
22,574
+10.0%
|
$22,574
$1.4 P/Share
|
|
Dec 06
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
2,300
+1.26%
|
$2,300
$1.35 P/Share
|
|
Dec 05
2022
|
Richard D. Pilnik Director |
BUY
Open market or private purchase
|
Direct |
35,000
+18.49%
|
$35,000
$1.39 P/Share
|
|
Dec 02
2022
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,855,847
+50.0%
|
$2,855,847
$1.24 P/Share
|
|
Dec 02
2022
|
Thomas Von Koch > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,855,847
-100.0%
|
$2,855,847
$1.24 P/Share
|
|
Dec 01
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
46,952
+10.55%
|
$46,952
$1.2 P/Share
|
|
Nov 30
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
2,970
+2.21%
|
$2,970
$1.19 P/Share
|
|
Nov 29
2022
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
18,125
+12.37%
|
$18,125
$1.19 P/Share
|
|
Nov 16
2022
|
Dietrich John Pauls President and CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+26.38%
|
$20,000
$1.21 P/Share
|
|
Jul 08
2022
|
Thomas Von Koch > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
207,974
+6.79%
|
$207,974
$1.33 P/Share
|
|
Jan 03
2022
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
15,026
+12.0%
|
$45,078
$3.58 P/Share
|
|
Jan 03
2022
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,773
+30.34%
|
$50,319
$3.58 P/Share
|
|
Jan 03
2022
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
23,762
+16.61%
|
$71,286
$3.58 P/Share
|
|
Jan 03
2022
|
Amy L. Burroughs Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,182
+16.61%
|
$33,546
$3.58 P/Share
|
|
Sep 15
2021
|
Harry W Alcorn Jr SVP, Clinical Operations |
BUY
Open market or private purchase
|
Direct |
15,000
+25.61%
|
$45,000
$3.8 P/Share
|
|
Aug 16
2021
|
Richard D. Pilnik Director |
BUY
Open market or private purchase
|
Direct |
15,000
+7.24%
|
$45,000
$3.25 P/Share
|
|
Aug 16
2021
|
Amy L. Burroughs Director |
BUY
Open market or private purchase
|
Direct |
44,950
+50.0%
|
$134,850
$3.15 P/Share
|
|
Aug 16
2021
|
Scott Kellen CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
10,000
+30.97%
|
$30,000
$3.15 P/Share
|
|
Aug 16
2021
|
Dietrich John Pauls President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+12.25%
|
$15,000
$3.14 P/Share
|
|
Aug 16
2021
|
Harry W Alcorn Jr SVP, Clinical Operations |
BUY
Open market or private purchase
|
Indirect |
399
+50.0%
|
$1,197
$3.07 P/Share
|
|
Aug 16
2021
|
Harry W Alcorn Jr SVP, Clinical Operations |
BUY
Open market or private purchase
|
Direct |
20,322
+21.28%
|
$60,966
$3.08 P/Share
|
|
Jan 01
2021
|
Richard D. Pilnik Director |
BUY
Grant, award, or other acquisition
|
Direct |
9,719
+10.76%
|
$77,752
$8.23 P/Share
|
|
Jan 01
2021
|
James T. Parsons Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,745
+26.08%
|
$61,960
$8.23 P/Share
|
|
Jan 01
2021
|
Randall Michael Giuffre Director |
BUY
Grant, award, or other acquisition
|
Direct |
7,441
+6.03%
|
$59,528
$8.23 P/Share
|
|
Dec 04
2020
|
Richard D. Pilnik Director |
BUY
Open market or private purchase
|
Direct |
10,000
+6.82%
|
$50,000
$5.37 P/Share
|
|
Nov 20
2020
|
Randall Michael Giuffre Director |
BUY
Open market or private purchase
|
Direct |
15,000
+12.14%
|
$60,000
$4.26 P/Share
|
|
Nov 09
2020
|
Scott Kellen CFO and Secretary |
BUY
Open market or private purchase
|
Direct |
2,000
+14.0%
|
$8,000
$4.19 P/Share
|